Business Standard

Reliance joins Rs 2 trillion m-cap club

Related News

Reliance Industries (RIL) today touched the Rs 2 trillion market capitalisation mark in mid-session trade, becoming the third Indian company after ONGC and Wipro to touch the milestone, even as the Sensex lost 149.52 points (1.04 per cent) on heavy profit-booking.
The RIL scrip rose to a 52-week high of Rs 1,444.80 during the intra-day trade, but ended in the red at Rs 1,414.55, which is 0.26 per cent below the yesterday's close of Rs 1,418.25.
RIL, however, continues to be the top market capitalisation company, with an m-cap of Rs 1,97,188.27 crore.
(market cap in Rs crore)
Reliance Industries  1,97,188.27 
ONGC  1,87,279.46
Bharti Airtel  1,50,032.03
Infosys  1,32,036.75
TCS  1,26,943.99
NTPC  1,17,168.56
While the Sensex lost the morning session's gain to end at 14,253.38 points, the S&P CNX Nifty declined 60.35 points (1.45 per cent) to end at 4,104.20 points.
Today's fall was also influenced by investors offloading their positions on the back of the expiry of February contracts.
FMCG firm Hindustan Lever (HLL), which plans to incorporate its parent company's name in its Indian identity to Hindustan Unilever, lost 0.7 per cent to close at Rs 203.75. The company posted 1.9 per cent fall in quarterly profits on rising raw material costs.


Read more on:   

Read More

Steel Strips Wheels soars on higher export sales in February

The company registered a 63% year-on-year growth in export sales of 88,020 steel wheel rims during the month of February 2013.

Quick Links


Market News

Sensex, Nifty retreat from record high levels

Sensex touched its all-time high of 22,875.17 and the broader Nifty kissed 6,861.60 figure for first time

Cardamom up 0.7% on strong demand

Spice for delivery in June gained 0.38%

Palm oil down 0.3% on subdued demand

Oil for delivery in May traded lower by 0.15%

Natco extends gains on US court ruling over generic Copaxone

US Supreme Court ruling paved the way to launch generic version of Teva's Copaxone

Shasun Pharma zooms 40% in three days ahead of board meeting

The board is scheduled to meet today to consider issuing convertible warrants/equity shares on a preferential basis to the promoters.

Back to Top